Voxelotor and Cariprazine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Voxelotor
Cariprazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Voxelotor (Oxbryta) can slow down a liver enzyme called CYP3A4. That enzyme is one of the main ways your body breaks down cariprazine (Vraylar). So when you take both, cariprazine and its active breakdown product can build up higher than usual in your body.
Higher levels can mean stronger effects and more side effects, like restlessness, trouble sitting still, sleepiness, or shakiness. The good news is this is very manageable. Your care team can simply use a lower cariprazine dose and keep a closer eye on how you're feeling. Please don't stop or change either medicine on your own. Just check in with your pharmacist or doctor.
Mechanism: Voxelotor is a moderate CYP3A4 inhibitor; cariprazine is a CYP3A4 substrate. Inhibition reduces metabolism, increasing exposure (AUC) of cariprazine and its active metabolite didesmethylcariprazine (DDCAR). Neither is a prodrug in a way that reverses this, so effect is increased.
Evidence/severity: Probable, rated major. Onset unspecified.
Management (per labeling for moderate CYP3A4 inhibitors):
- Initiating cariprazine (schizophrenia/bipolar mania): 1.5 mg every other day, titrate cautiously per response/tolerability.
- Bipolar depression or adjunctive MDD: 1.5 mg every other day.
- Stable on 1.5 or 3 mg daily then adding inhibitor: reduce to 1.5 mg every other day.
- Stable on 4.5 or 6 mg daily: reduce to 1.5 mg daily.
- On inhibitor discontinuation: dose may be increased per response.
Monitor for extrapyramidal symptoms, akathisia, and sedation.
What happens
Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure
Interaction Deep Dive
Giving cariprazine (which is a CYP3A4 substrate) together with a moderate CYP3A4 inhibitor may raise the levels of both cariprazine and didesmethylcariprazine, its active metabolite. If cariprazine is being started in a patient already receiving a moderate CYP3A4 inhibitor (for schizophrenia or bipolar mania), the recommended starting dose is 1.5 mg orally every other day, which may be raised to 1.5 mg orally every other day if warranted, guided by clinical response and tolerability. For patients on a moderate CYP3A4 inhibitor being treated for bipolar depression or receiving cariprazine as adjunctive therapy for MDD, the dose is 1.5 mg orally every other day. When a moderate CYP3A4 inhibitor is added to an established cariprazine regimen, the dose should be modified as follows: for those currently taking 1.5 or 3 mg once daily, reduce cariprazine to 1.5 mg orally every other day upon starting the inhibitor; for those currently taking cariprazine 4.5 or 6 mg once daily, reduce it to 1.5 mg orally once daily upon starting the inhibitor. If the moderate CYP3A4 inhibitor is later stopped, an increase in the cariprazine dose may be required, depending on clinical response and tolerability1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
This is manageable with dose tailoring and monitoring. Because voxelotor can raise cariprazine levels, your care team will often use a lower cariprazine dose and watch you more closely.
- Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise.
- Your team may set a reduced cariprazine dose (the label gives specific lower dosing for people on a moderate CYP3A4 inhibitor) and adjust it based on how you respond and tolerate it.
- If voxelotor is later stopped, your cariprazine dose may need to be raised again.
- Tell your pharmacist or doctor about any new restlessness, muscle stiffness, tremor, or drowsiness.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) In drug interaction studies, giving cariprazine 1.5 mg/day together with erythromycin (a moderate CYP3A4 inhibitor) 500 mg twice daily for 21 days led to an increase in cariprazine AUC (0 to 24 hours) and Cmax by roughly 50% 1. In one study that enrolled only White males receiving cariprazine 1.5 mg/day and erythromycin 500 mg twice daily (n=40), AUCs rose by 38% (cariprazine), 11% (desmethylcariprazine, an active metabolite), and 60% (didesmethylcariprazine, an active metabolite), while Cmax increased by 34%, 16%, and 62%, respectively. Tmax was not altered by coadministration with erythromycin 2.
Common questions
Can I take Voxelotor and Cariprazine together?
Voxelotor can raise cariprazine levels and increase side effects, but your care team can manage this safely by lowering the cariprazine dose and monitoring you. Keep taking both as prescribed and check in with your pharmacist or doctor. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Voxelotor and Cariprazine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Voxelotor and Cariprazine interaction managed?
This is manageable with dose tailoring and monitoring. Because voxelotor can raise cariprazine levels, your care team will often use a lower cariprazine dose and watch you more closely. Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise. Your team may set a reduced cariprazine dose (the label gives specific lower dosing for people on a moderate CYP3A4 inhib… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Voxelotor or Cariprazine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
- Szabo M, Hujber Z, Harsanyi J, et al: Coadministration of cariprazine with a moderate CYP3A4 inhibitor in patients with schizophrenia: implications for dose adjustment and safety monitoring. Clin Pharmacokinet 2024; 63(10):1501-1510. PubMed
Keep reading about Voxelotor
Keep reading about Cariprazine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist